Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche To Appeal NICE's Rejection Of Herceptin For HER2-positive Stomach Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

The latest appraisals from NICE include the rejection of Herceptin use in gastric cancer but give positive recommendations to RoActemra and TNF-inhibitors in rheumatoid arthritis.

You may also be interested in...



NICE Rejects Javlor, But Could Products For Unmet Clinical Needs Be Rethought?

U.K. cost watchdog rejects Pierre Fabre's Javlor even though it extended the survival of patients with metastatic bladder cancer.

NICE Rejects Javlor, But Could Products For Unmet Clinical Needs Be Rethought?

U.K. cost watchdog rejects Pierre Fabre's Javlor even though it extended the survival of patients with metastatic bladder cancer.

Sanofi-Aventis Receives Positive Final NICE Guidance On Multaq

U.K. spending watchdog recommends Multaq for atrial fibrillation and biologic therapies for rheumatoid arthritis and psoriatic arthritis, but rejects imatinib for adjuvant therapy of gastrointestinal stromal tumors.

Topics

Latest News
UsernamePublicRestriction

Register

PS070993

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel